Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

World Sleep 2022 | Augmentation monitoring in RLS

Evi Holzknecht • 14 Mar 2022
World Sleep 2022
Restless Legs Syndrome Sleep Disorders

Augmentation is defined as a worsening of restless legs syndrome (RLS) symptoms after starting a dopaminergic medication to treat RLS. Evi Holzknecht, MD, Medical University of Innsbruck, Innsbruck, Austria, describes the benefits of systematic monitoring of augmentation risk factors in RLS. According to Dr. Holzknecht, informing therapy regimens based on screening of patient-reported outcomes could lead to reduced augmentation rates. This interview was recorded at the World Sleep Congress 2022 in Rome, Italy.

More from Evi Holzknecht

Gender differences in description of RLS symptoms
1:44
Gender differences in description of RLS symptoms
Evi Holzknecht • 14 Mar 2022
Risk prediction and treatment options in RLS
1:25
Risk prediction and treatment options in RLS
Evi Holzknecht • 14 Mar 2022
Predictors of augmentation in RLS
1:50
Predictors of augmentation in RLS
Evi Holzknecht • 14 Mar 2022

Related Videos

Treatment selection in CSA: when to switch, add on or reconsider therapy
2:15
Treatment selection in CSA: when to switch, add on or reconsider therapy
M. Safwan Badr • 9 Nov 2026
What’s changed in the 2025 AASM CSA guideline: new roles for ASV and phrenic nerve stimulation
2:36
What’s changed in the 2025 AASM CSA guideline: new roles for ASV and phrenic nerve stimulation
M. Safwan Badr • 9 Nov 2026
Three key principles for implementing the 2025 AASM CSA guideline in clinical practice
1:50
Three key principles for implementing the 2025 AASM CSA guideline in clinical practice
M. Safwan Badr • 9 Nov 2026
Could pathophysiology-driven and combination therapies shape future CSA care and AASM guidelines?
3:23
Could pathophysiology-driven and combination therapies shape future CSA care and AASM guidelines?
M. Safwan Badr • 9 Nov 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals